文献速递前列腺癌

结合多参数前列腺磁共振、临床特征和先进血清生物标志物优化活检初治男性临床显著前列腺癌的检测:列线图的开发与验证

Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-03-27

本研究基于11家医院体系2018年3月至2021年6月收治的1494例活检初治、PSA 2-20 ng/mL且活检前接受多参数前列腺磁共振(mpMRI)的男性,开发了预测诊断性活检时临床显著前列腺癌(csPCa,≥GG2)和高级别前列腺癌(≥GG3)的列线图。列线图整合年龄、种族、最高PIRADS评分、前列腺健康指数(PHI)、游离PSA百分比和PSA密度,在训练队列中AUC≥0.885,在独立验证队列(366例)中AUC≥0.896;在独立验证队列中,以csPCa概率20%为活检阈值,含PHI的≥GG2模型可减少39.1%(143/366)的活检,仅漏诊0.8%(1/124)的csPCa。

要点

  • 列线图整合mpMRI、血清标志物和临床特征,训练队列AUC≥0.885,独立验证队列AUC≥0.896。
  • 含PHI的≥GG2模型在20%概率阈值下可减少39.1%活检,仅漏诊0.8%的csPCa。
  • 列线图在线工具可辅助PSA 2-20 ng/mL活检初治男性的活检决策。

核心结论

  • 研究开发了结合血清检测和mpMRI的列线图,帮助临床医生对PSA 2-20 ng/mL、正在考虑活检的患者进行风险分层。
  • 列线图已在线提供(https://rossnm1.shinyapps.io/MynMRIskCalculator/)以辅助活检决策。

研究设计与样本

  • 列线图开发队列为2018年3月至2021年6月在本11家医院体系就诊的1494例活检初治、PSA 2-20 ng/mL且活检前接受mpMRI的男性。
  • 结局为诊断性活检时临床显著前列腺癌(csPCa,≥GG2)和高级别前列腺癌(≥GG3)的存在。
  • 使用多变量逻辑回归中的显著变量,分别为有总PSA、游离PSA百分比或前列腺健康指数(PHI)的男性开发列线图。
  • 列线图在内部验证,并在2021年7月至2022年2月在本医院体系就诊的366例男性的独立队列中评估。

主要发现

  • 1494例男性中1031例(69%)在mpMRI初始评估后接受活检,其中493例(47.8%)发现≥GG2前列腺癌,271例(26.3%)发现≥GG3前列腺癌。
  • 多变量分析中,年龄、种族、最高PIRADS评分、有PHI时的PHI、有游离PSA百分比时的游离PSA百分比和PSA密度是≥GG2和≥GG3前列腺癌的显著预测因素。
  • 列线图在训练队列中AUC≥0.885,在独立验证队列中AUC≥0.896。
  • 在独立验证队列中,含PHI的≥GG2前列腺癌模型以csPCa概率20%为活检阈值,节省39.1%(143/366)的活检,仅漏诊0.8%(1/124)的csPCa。

关键数值与推荐

  • csPCa定义为≥GG2(Grade Group 2)前列腺癌;高级别前列腺癌定义为≥GG3前列腺癌。
  • 活检阈值:csPCa概率20%时,含PHI的≥GG2模型节省39.1%(143/366)活检,漏诊0.8%(1/124)csPCa。
  • 训练队列AUC≥0.885,独立验证队列AUC≥0.896。

临床怎么用

  • 列线图可用于PSA 2-20 ng/mL、活检初治、已行mpMRI的男性,辅助活检决策。
  • 列线图在线工具(https://rossnm1.shinyapps.io/MynMRIskCalculator/)可供临床医生使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop nomograms that predict the detection of clinically significant prostate cancer (csPCa, defined as ≥GG2 [Grade Group 2]) at diagnostic biopsy based on multiparametric prostate MRI (mpMRI), serum biomarkers, and patient clinicodemographic features. MATERIALS AND METHODS: Nomograms were developed from a cohort of biopsy-naïve men presenting to our 11-hospital system with prostate specific antigen (PSA) of 2-20 ng/mL who underwent pre-biopsy mpMRI from March 2018-June 2021 (n = 1494). The outcomes were the presence of csPCa and high-grade prostate cancer (defined as ≥GG3 prostate cancer). Using significant variables on multivariable logistic regression, individual nomograms were developed for men with total PSA, % free PSA, or prostate health index (PHI) when available. The nomograms were both internally validated and evaluated in an independent cohort of 366 men presenting to our hospital system from July 2021-February 2022. RESULTS: 1031 of 1494 men (69%) underwent biopsy after initial evaluation with mpMRI, 493 (47.8%) of whom were found to have ≥GG2 PCa, and 271 (26.3%) were found to have ≥GG3 PCa. Age, race, highest PIRADS score, prostate health index when available, % free PSA when available, and PSA density were significant predictors of ≥GG2 and ≥GG3 PCa on multivariable analysis and were used for nomogram generation. Accuracy of nomograms in both the training cohort and independent cohort were high, with areas under the curves (AUC) of ≥0.885 in the training cohort and ≥0.896 in the independent validation cohort. In our independent validation cohort, our model for ≥GG2 prostate cancer with PHI saved 39.1% of biopsies (143/366) while only missing 0.8% of csPCa (1/124) with a biopsy threshold of 20% probability of csPCa. CONCLUSIONS: Here we developed nomograms combining serum testing and mpMRI to help clinicians risk stratify patients with elevated PSA of 2-20 ng/mL who are being considered for biopsy. Our nomograms are available at https://rossnm1.shinyapps.io/MynMRIskCalculator/ to aid with biopsy decisions.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Siddiqui MR, Li EV, Kumar SKSR, et al. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men. Prostate Cancer Prostatic Dis. 2023. PMID: 36973367. doi:10.1038/s41391-023-00660-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。